Three independent discounted-cash-flow-style models value Acadia Pharmaceuticals Inc. every trading day. 0 of 3 currently price ACAD above its market price.
| Free Cash Flow model | $-53.16 |
| Excess Profit model | $-55.89 |
| Residual Earnings model | $-1.59 |
| Dividend Discount model | — |
| Piotroski F-Score | 5 / 9 |
| Return on invested capital | +6.4% |
| Net debt / EBITDA | 0.6× |
| Gross margin | +91.7% |
| Revenue CAGR | +30.3% |
| Cash conversion | 0.3× |
| Dividend yield | — |
| Buyback yield | -102669.5% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open ACAD in StockKitty